Viatris Inc. (VTRS) Stock Price & Analysis
Viatris Inc. (VTRS) closed at USD 18.48 on Thursday, October 22, 2026, up 0.16% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 18.45; the Oct 22, 2026 session ranged USD 18.35–18.66 on volume of 5,435,547 shares. Market capitalization is $21.23B, with a 52-week range of USD 9.92–18.75 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:16 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VTRS.md
Key facts (VTRS)
- Last four reported quarters (through Jun 30, 2026): revenue $14.7B, net income -$411M (-2.8% margin), free cash flow $1.95B (SEC filings).
- 3 of 80 tracked superinvestors hold VTRS (13F, Q2 2026): 0 new, 2 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $810K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.50 on a 1–5 scale) (12 analysts), mean target USD 19.9 (range 13–26).
- Total return with dividends: 1Y +85.6% vs S&P 500 +14.9%; 5Y +63.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.64, revenue estimate $3.79B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VTRS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B | $14.7B |
| Gross profit | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B | — |
| Operating income | -$34.0M | $1.61B | $766M | $10.1M | -$2.66B | -$87.3M |
| Net income | -$1.27B | $2.08B | $54.7M | -$634M | -$3.51B | -$411M |
| EPS (diluted) | -$1.05 | $1.71 | $0.05 | -$0.53 | -$3.00 | — |
| Free cash flow | $2.56B | $2.59B | $2.52B | $1.98B | $1.94B | $1.95B |
| Gross margin | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% | — |
| Operating margin | -0.2% | 9.9% | 5.0% | 0.1% | -18.6% | -0.6% |
| Net margin | -7.1% | 12.8% | 0.4% | -4.3% | -24.6% | -2.8% |
| Revenue growth | +49.7% | -9.1% | -5.1% | -4.5% | -3.0% | — |
| Cash + short-term investments | $739M | $1.30B | $1.03B | $773M | $1.36B | — |
| Total debt | $21.6B | $19.3B | $18.1B | $14.0B | $14.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (VTRS)
P/S 1.4x · P/FCF 10.9x · P/B 1.5x · FCF yield 9.21% · Earnings yield -1.93% · Buyback yield (TTM) 1.43%
P/E at fiscal year-ends: Dec 2023 239.0x.
Superinvestors (SEC 13F-HR, Q2 2026) (VTRS)
3 of 80 tracked investors hold VTRS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Christopher Davis | Davis Advisors | 5.13% | $1.19B | Reduced -3.8% |
| Bill Miller | Miller Value Partners | 2.75% | $11.6M | Added +0.2% |
| David Einhorn | Greenlight Capital | 1.13% | $44.0M | Added +52.6% |
Insider sales (SEC Form 4, open-market, last ~7 months) (VTRS)
1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Campbell Paul | See Remarks | 50,076 | $810K | 13.7% | Yes (adopted March 24, 2026) | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (VTRS)
Consensus Hold (mean 2.50 on a 1–5 scale), 12 analysts; mean target USD 19.9 (low 13, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | JP Morgan | Target raised | Neutral | $18 → $20 |
| 2026-10-05 | UBS | Target raised | Buy | $23 → $26 |
| 2026-09-23 | Oppenheimer | Initiated | Outperform | $25 |
| 2026-09-16 | Piper Sandler | Target raised | Neutral | $12 → $13 |
| 2026-09-09 | Leerink Partners | Initiated | Outperform | $20 |
| 2026-09-08 | Argus Research | Target raised | Buy | $15 → $20 |
Total return (dividends reinvested) (VTRS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +85.6% | +63.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +86.0% | +10.3% |
| Volatility (annualized) | 32.2% | 36.3% |
| Max drawdown | -19.0% (Feb 2026→Mar 2026) | -42.9% (Jan 2022→Apr 2025) |
VTRS revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Developed Markets | $2.19B | 58.6% | +3.5% |
| Greater China | $713.8M | 19.1% | +21.2% |
| Emerging Markets | $542.3M | 14.5% | -2.3% |
| Japan, Australia and New Zealand | $296.1M | 7.9% | -3.1% |
| Total revenue | $3.75B | 100% | — |
VTRS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Brands | $1.12B | 30.0% | +0.1% |
| Generics | $1.07B | 28.6% | +7.4% |
| Lipitor | $452.2M | 12.1% | +16.6% |
| Norvasc | $200.2M | 5.3% | +9.6% |
| EpiPen® Auto-Injectors | $129.2M | 3.4% | -5.6% |
| Lyrica ® | $120.6M | 3.2% | -5.9% |
| Viagra ® | $112.9M | 3.0% | +12.6% |
| Creon ® | $97.4M | 2.6% | +6.6% |
| Celebrex ® | $76.4M | 2.0% | +9.1% |
| Zoloft ® | $71.4M | 1.9% | +16.9% |
| Yupelri ® | $70.7M | 1.9% | +6.2% |
| Effexor ® | $66.7M | 1.8% | +5.7% |
| Dymista ® | $39.8M | 1.1% | -17.8% |
| Amitiza ® | $39.4M | 1.1% | -5.3% |
| Xalabrands | $38.8M | 1.0% | -4.7% |
| Xanax ® | $38.1M | 1.0% | +12.4% |
| Total revenue | $3.75B | 100% | — |
VTRS revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $3.01B | 21.1% | -12.5% |
| China | $2.08B | 14.6% | +8.8% |
| Total revenue | $14.25B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
VTRS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | IQVIA HOLDINGS INC. (IQV) | “Unless otherwise indicated, industry data included in this Item 1 are sourced from IQVIA Holdings Inc. and are for the twelve months ended November 2025 and Viatris product and other company data included in this Item 1 are from internal sources and are as of November 30, 2025.” |
| Competitor | Pfizer (PFE) | “Pfizer, however, has agreed to retain various matters – including certain specified competition law matters – to the extent they arise from conduct during the pre-Distribution period and has agreed to indemnify the Company for liabilities arising out of such matters.” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name VTRS in their SEC reports
| Relationship to VTRS | Company | Filing | Sentence |
|---|---|---|---|
| partner | Opus Genetics, Inc. (IRD) | 10-K Mar 12, 2026 | “In November 2022, we entered into a license and collaboration agreement (the "Viatris License Agreement") with a company now known as Viatris, Inc. ("Viatris"), pursuant to” |
| partner | LEXICON PHARMACEUTICALS, INC. (LXRX) | 10-K Mar 5, 2026 | “We entered into an exclusive license agreement with Viatris Inc. in October 2024 under which we granted Viatris an exclusive, royalty-bearing right and license to develop and commercialize sotagliflozin in the licensed territory.” |
| customer | HALOZYME THERAPEUTICS, INC. (HALO) | 10-K Feb 17, 2026 | “In December 2025, we entered into a commercial license and supply agreement with Viatris under which we license and supply an auto-injector product for self-administered SC selatogrel for the treatment of acute myocardial infarction in adult patients.” |
VTRS customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 11% of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name it.
VTRS company outlook (results filed Aug 6, 2026)
- “In addition, we further strengthened our balance sheet and reduced our gross leverage ratio to 2.9x." [1] Viatris is not providing forward-looking guidance for U.S.”
- “GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 Adjusted EBITDA or Adjusted EPS guidance.”
- “GAAP net cash provided by operating activities for 2026 is estimated to be between $1.9 billion and $2.1 billion, with a midpoint of approximately $2.0 billion. 2026 financial guidance ranges as provided on August 6, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted.”
- “Please see "2026 Financial Guidance" and "Non-GAAP Financial Measures" for additional information.”
Quoted word-for-word from the SEC 8-K results press release.
VTRS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.64 | $0.64 | -0.4% | $3.79B | 10 |
| Next quarter (ends Dec 2026) | $0.59 | $0.62 | -3.4% | $3.72B | 10 |
| Current fiscal year (ends Dec 2026) | $2.52 | $2.46 | +2.4% | $14.78B | 11 |
| Next fiscal year (ends Dec 2027) | $2.70 | $2.63 | +2.6% | $15.14B | 11 |
VTRS options: expected move
Options price a move of about ±9.5% (±$1.75) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±8.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 34.9% | ±9.5% |
| Dec 18, 2026 | 56 | 35.9% | ±11.4% |
| Jan 15, 2027 | 84 | 33.7% | ±13.0% |
| Apr 16, 2027 | 175 | 34.3% | ±18.7% |
30-day implied volatility 37.1% vs 24.3% realized over the last 30 trading days. Put/call ratio (volume) 0.07. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:16 UTC)
| Price | USD 18.48 |
|---|---|
| Change | ▲ 0.16% (up) |
| Previous Close | USD 18.45 |
| Open | USD 18.45 |
| Day Range | USD 18.35 – 18.66 |
| 52-Week Range | USD 9.92 – 18.75 |
| Volume | 5,435,547 shares |
| Market Cap | $21.23B |
| Exchange | NMS |
Technical Analysis (VTRS)
Nexqual's technical model rates VTRS "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:16 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.13 (neutral) |
| vs SMA50 | Above (USD 17.15) |
| MACD | 0.35 (positive) |
Analyst Ratings (VTRS)
Wall Street analysts rate VTRS "Hold" based on 12 analysts, with a mean price target of USD 19.9 (range USD 13–26), per Nexqual as of October 23, 2026 at 09:16 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 19.9 |
| High Target | USD 26 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 7 / 4 / 1 |
Earnings (VTRS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.64 |
| Revenue Estimate | $3.79B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.69 vs est 0.6 ▲ beat |
| 2026-03-31 | USD 0.59 vs est 0.5 ▲ beat |
| 2025-12-31 | USD 0.57 vs est 0.53 ▲ beat |
| 2025-09-30 | USD 0.67 vs est 0.62 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financials & Fundamentals (VTRS)
| Total Revenue | $14.74B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.90% |
| Gross Margin | +40.31% |
| Operating Margin | +12.55% |
| Profit Margin | -2.79% |
| ROE | -2.75% |
| Debt / Equity | 0.96 |
| Current Ratio | 1.59 |
| Total Cash | $1.51B |
| Total Debt | $13.62B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.95B (13.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financial Health Score (VTRS)
Nexqual rates Viatris Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:16 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 40%, operating 13% (last 12 months) |
| Balance Sheet | Mixed — $1.36B cash and investments vs $14.4B debt (Dec 2025, SEC) |
| Cash Flow | Solid — FCF $1.95B (last 4 quarters to Jun 2026, SEC), 13% margin |
| Efficiency | Critical — ROE -3%, ROA 2.7% |
Ownership (VTRS)
| Insider Ownership | +0.32% |
|---|---|
| Institutional Ownership | +94.10% |
| Shares Outstanding | 1.15B |
| Float | 1.14B |
| Short % of Float | +3.67% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Leadership (VTRS)
Viatris Inc. is led by Scott Andrew Smith, CEO & Director, per Nexqual as of October 23, 2026 at 09:16 UTC.
| CEO & Director | Scott Andrew Smith |
|---|---|
| Interim CFO, Chief Accounting Officer & Corporate Controller | Paul B. Campbell |
Major Backers & Investors (VTRS)
Notable institutional backers of Viatris Inc. include FMR, LLC, Davis Selected Advisers, Price (T.Rowe) Associates Inc, according to Nexqual as of October 23, 2026 at 09:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.42% |
| Davis Selected Advisers | 6.55% |
| Price (T.Rowe) Associates Inc | 5.94% |
| Fidelity | 3.25% |
| Rubric Capital Management LP | 2.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.35% |
| BlackRock | 7.49% |
| State Street | 4.62% |
| Geode Capital | 2.86% |
| Dimensional Fund Advisors | 2.61% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
From Viatris Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Viatris retained some selective R&D capabilities in API. •In July 2024, the Company completed the divestiture of its OTC Business to Cooper Consumer Health, a leading European OTC drug manufacturer and distributor.
- Viatris' confidence in the delivery of its pipeline is rooted in its strong historic development programs and list of firsts, including the first FDA approvals of the generic versions of Advair Diskus® (Wixela Inhub®), Restasis®, Symbicort® (Breyna™), and Venofer®.
- Viatris offers a number of these important medicines to patients, including Breyna™ Inhalation Aerosol, the first FDA-approved generic version of Symbicort®, Wixela Inhub®, the first generic of Advair Diskus®, glatiramer acetate injection, a generic version of Copaxone®, and its generic iron sucrose injection.
- The Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise.
Partnerships
- After completing the divestiture of its API business in India, Viatris continues to maintain some selective R&D capabilities in API and believes it has access to adequate API supplies through a manufacturing and supply agreement with the API business buyer and Viatris' supply agreements with other manufacturers.
- As the Company continues to expand its portfolio of more innovative, best-in-class, patent-protected assets, the Company may enter into more financial commitments in connection with agreements with its collaboration partners that provide for certain services, as well as cross manufacturing, development and licensing arrangements.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to the U.S. Foreign Corrupt Practices Act, U.S. Foreign Extortion Prevention Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.
- We operate in jurisdictions that have experienced corruption, bribery, pay-offs and other similar practices from time-to-time and, in certain circumstances, such practices may be local custom.
- We may submit patent applications covering the API, formulation, methods of making, and/or methods of use for our branded products and branded product candidates.
- We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UTHR | United Therapeutics Corporation | USD 584.79 | ▲ 3.78% |
| NBIX | Neurocrine Biosciences, Inc. | USD 143.29 | ▲ 1.4% |
| ZTS | Zoetis Inc. | USD 82 | ▲ 2.99% |
| ELAN | Elanco Animal Health Incorporat | USD 22.69 | ▲ 0.62% |
| RDY | Dr. Reddy's Laboratories Ltd | USD 13.23 | ▲ 0.3% |
| HLN | Haleon plc | USD 10.37 | ▲ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:16 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt